Belgium· BE-AMP-SAM446817-00
Vipidia 25 mg
A alogliptin product containing alogliptin benzoate, registered in Belgium by Takeda Pharma. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Alogliptin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BH04 (alogliptin), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Alogliptin · ATC A10BH04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Polandprice
- United Kingdom
Price per daily dose
What a daily dose of alogliptin costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alogliptin · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- IT Italy$4.54
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Alogliptin Benzoate
- Manufacturer
- Takeda Pharma
- Country
- Belgium (BE)
- ATC code
- A10BH04
- ATC class
- Alogliptin
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
2 priced- be_apb3113172EUR 51.87
- be_apb3113180EUR 128.64
- be_apb7707961
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
312 interactions on record for alogliptin.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alogliptin · interactions on record
312 records
- 3 severe
- 269 moderate
- 40 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Alogliptin in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cb551a95-5fcf-4179-bb0c-62be7f765941 GET /v1/drugs/cb551a95-5fcf-4179-bb0c-62be7f765941?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Vipidia 25 mg",
"name_fr": "Vipidia 25 mg",
"name_nl": "Vipidia 25 mg",
"amp_code": "SAM446817-00",
"strengths": [
"25.0000",
"25.0000"
],
"pack_count": 10,
"substances": [
"Alogliptin Benzoate",
"Alogliptin",
"Mannitol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Alogliptin",
"authorisation_numbers": [
"EU/1/13/844/019",
"EU/1/13/844/021",
"EU/1/13/844/020",
"EU/1/13/844/023",
"EU/1/13/844/022",
"EU/1/13/844/025",
"EU/1/13/844/024",
"EU/1/13/844/027",
"EU/1/13/844/026",
"EU/1/13/844/030"
]
}See everything about alogliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.